These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 37772407)

  • 1. Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1.
    Gross AM; Plotkin SR; Watts NB; Fisher MJ; Klesse LJ; Lessing AJ; McManus ML; Larson AN; Oberlander B; Rios JJ; Sarnoff H; Simpson BN; Ullrich NJ; Stevenson DA
    Clin Trials; 2024 Feb; 21(1):29-39. PubMed ID: 37772407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials.
    Staedtke V; Anstett K; Bedwell D; Giovannini M; Keeling K; Kesterson R; Kim Y; Korf B; Leier A; McManus ML; Sarnoff H; Vitte J; Walker JA; Plotkin SR; Wallis D
    Clin Trials; 2024 Feb; 21(1):51-66. PubMed ID: 37937606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.
    Merker VL; Thompson HL; Wolters PL; Buono FD; Hingtgen CM; Rosser T; Barton B; Barnett C; Smith T; Haberkamp D; McManus ML; Baldwin A; Moss IP; Röhl C; Martin S
    Clin Trials; 2024 Feb; 21(1):6-17. PubMed ID: 38140900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofibromatosis: part 2--clinical management.
    Batista PB; Bertollo EM; Costa Dde S; Eliam L; Cunha KS; Cunha-Melo JR; Darrigo Junior LG; Geller M; Gianordoli-Nascimento IF; Madeira LG; Mendes HM; Miranda DM; Mata-Machado NA; Morato EG; Pavarino ÉC; Pereira LB; Rezende NA; Rodrigues Lde O; Sette JB
    Arq Neuropsiquiatr; 2015 Jun; 73(6):531-43. PubMed ID: 26083891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials.
    Sundby RT; Rhodes SD; Komlodi-Pasztor E; Sarnoff H; Grasso V; Upadhyaya M; Kim A; Evans DG; Blakeley JO; Hanemann CO; Bettegowda C
    Clin Trials; 2024 Feb; 21(1):40-50. PubMed ID: 37904489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.
    Thompson HL; Grabowski J; Franklin B; Koetsier KS; Welling DB
    Clin Trials; 2024 Feb; 21(1):18-28. PubMed ID: 38321701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration.
    Merker VL; Gross AM; Widemann BC; Plotkin SR
    Clin Trials; 2024 Feb; 21(1):3-5. PubMed ID: 37776044
    [No Abstract]   [Full Text] [Related]  

  • 8. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.
    Ferner RE; Bakker A; Elgersma Y; Evans DGR; Giovannini M; Legius E; Lloyd A; Messiaen LM; Plotkin S; Reilly KM; Schindeler A; Smith MJ; Ullrich NJ; Widemann B; Sherman LS
    Am J Med Genet A; 2019 Jun; 179(6):1098-1106. PubMed ID: 30908866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
    Fisher MJ; Belzberg AJ; de Blank P; De Raedt T; Elefteriou F; Ferner RE; Giovannini M; Harris GJ; Kalamarides M; Karajannis MA; Kim A; Lázaro C; Le LQ; Li W; Listernick R; Martin S; Morrison H; Pasmant E; Ratner N; Schorry E; Ullrich NJ; Viskochil D; Weiss B; Widemann BC; Zhu Y; Bakker A; Serra E
    Am J Med Genet A; 2018 May; 176(5):1258-1269. PubMed ID: 29681099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online survey.
    Wolters PL; Ghriwati NA; Baker M; Martin S; Berg D; Erickson G; Franklin B; Merker VL; Oberlander B; Reeve S; Rohl C; Rosser T; Vranceanu AM
    Clin Trials; 2024 Feb; 21(1):73-84. PubMed ID: 37962219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.
    Blakeley JO; Bakker A; Barker A; Clapp W; Ferner R; Fisher MJ; Giovannini M; Gutmann DH; Karajannis MA; Kissil JL; Legius E; Lloyd AC; Packer RJ; Ramesh V; Riccardi VM; Stevenson DA; Ullrich NJ; Upadhyaya M; Stemmer-Rachamimov A
    Am J Med Genet A; 2017 Jun; 173(6):1714-1721. PubMed ID: 28436162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
    Merker VL; Dai A; Radtke HB; Knight P; Jordan JT; Plotkin SR
    BMC Health Serv Res; 2018 Aug; 18(1):668. PubMed ID: 30157837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
    Tamura R
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.
    Vranceanu AM; Merker VL; Park E; Plotkin SR
    J Neurooncol; 2013 Sep; 114(3):257-62. PubMed ID: 23817811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Review of Recent and Ongoing Clinical Trials in Patients With the Neurofibromatoses.
    Acar S; Nieblas-Bedolla E; Armstrong AE; Hirbe AC
    Pediatr Neurol; 2022 Sep; 134():1-6. PubMed ID: 35759947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
    Blakeley JO; Plotkin SR
    Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
    Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
    Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials.
    Wolters PL; Martin S; Merker VL; Gardner KL; Hingtgen CM; Tonsgard JH; Schorry EK; Baldwin A;
    Neurology; 2013 Nov; 81(21 Suppl 1):S6-14. PubMed ID: 24249806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Diagnosis and Management of Neurofibromatosis Type 1.
    Ly KI; Blakeley JO
    Med Clin North Am; 2019 Nov; 103(6):1035-1054. PubMed ID: 31582003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
    Ahlawat S; Fayad LM; Khan MS; Bredella MA; Harris GJ; Evans DG; Farschtschi S; Jacobs MA; Chhabra A; Salamon JM; Wenzel R; Mautner VF; Dombi E; Cai W; Plotkin SR; Blakeley JO; ;
    Neurology; 2016 Aug; 87(7 Suppl 1):S31-9. PubMed ID: 27527647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.